Scientists have detected that a previously overlooked gene behaviour could potentially lead to a new way to diagnose Alzheimer’s earlier.
An international research team’s findings – discovered in mice and confirmed in human samples – suggest that the gene presenilin-1 (PSEN1) should be monitored as a ‘biomarker’: to see what environmental triggers, such as lifestyle and nutrition, can influence brain function and neurodegeneration or/and to see how well the body responds to a treatment for the disease.
The study, led by Professor Andrea Fuso at the Sapienza University of Rome, is the first to observe that the methylation (when the DNA activity of a gene can change, without changing the actual DNA sequence) of the gene PSEN1 is a common feature of Alzheimer’s.
The results of the study appear to show that PSEN1, which was already known to behave differently for people with Alzheimer’s, may have been dismissed in previous studies due to methods used to investigate DNA methylation.
The limitations of comparing results from mouse models and humans include mouse stages of development and neurodegeneration not corresponding precisely to those of human ageing.
In this study, the team noted that the blood and brain samples were obtained from different subjects. They suggested that future studies should analyse DNA from the same individuals, and in a larger cohort, in order to validate this potential biomarker.
However, Prof. Fuso believes that the new results do offer “an exciting new area of investigation”.
“We’ve detected an early sign of the disease in a DNA modification, or epigenetic marker, that was previously overlooked, and that could even provide a starting point for developing new therapies, as well as earlier diagnosis,” he added.
Worldwide, nearly 50 million people have Alzheimer’s or related dementia. Yet, only one in four people with Alzheimer’s disease have been diagnosed.
The earlier Alzheimer’s can be detected, the better the chance of using treatment to delay the onset of severe dementia.
Epigenetic alternations to genes, induced by environmental triggers such as lifestyle and nutrition, can influence brain function and neurodegeneration.
Evidence from animal models has found that changes to regulation of the PSEN1 gene is associated with Alzheimer’s-like pathology, but only a handful of studies have investigated DNA modification of the gene in humans.
For the current study, the authors analysed patterns of DNA modification that affect the expression of the PSEN1 gene during brain development and during the progression of Alzheimer’s in mice.
They checked the results in humans by analysing post-mortem human brain tissue from Alzheimer’s patients and from prenatal and postnatal babies and adolescents.
To see whether changes to DNA methylation could be detected in human blood, they analysed blood samples from 20 patients with late-onset Alzheimer’s disease, comparing the results to 20 healthy controls.
The analysis of blood samples was able to detect lower PSEN1-related DNA methylation in Alzheimer’s patients compared to controls. The difference was significant, although not as large as in brain samples.
As lower methylation was detectable in the blood, and is associated with higher expression of PSEN1, it could offer a new way to diagnose Alzheimer’s early, and less invasively, than sampling brain tissue.
Are you worried you might develop Alzheimer’s or dementia?
If you enjoy our content, don’t keep it to yourself. Share our free eNews with your friends and encourage them to sign up.